-
Uncategorized1 month agoSTAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. And to...
-
Uncategorized1 month ago
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit...
-
Uncategorized1 month ago
Next Gen Leadership Awards Presented at the AGBT Agricultural Meeting
Last month, the AGBT Agricultural Meeting was held in Phoenix, Arizona. The conference is focused on agricultural genomics—plant and animal genetics. During the meeting, the recipients...
-
Uncategorized1 month ago
Atara, Pierre Fabre’s cell therapy to get another shot at FDA approval
There’s new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3...
-
Uncategorized1 month ago
Sanofi requests removal of Tzield from CNPV program after Høeg gets involved
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. It’s far...
-
Uncategorized1 month ago
Pennsylvania sues AI chatbot company for posing as a licensed doctor
Pennsylvania sues AI chatbot company for posing as a licensed doctor
-
Uncategorized1 month ago
Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery will take a long time, according to...
-
Uncategorized1 month agoSTAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agency’s main...
-
Uncategorized1 month ago
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition...
-
Uncategorized1 month agoHospital shootings steadily increased since 2000
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. I was charmed by this profile...
